154 related articles for article (PubMed ID: 12243733)
1. Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice.
Rafi-Janajreh A; Tongren JE; Kensil C; Hackett C; Candal F; Lal A; Udhayakumar V
Exp Parasitol; 2002 May; 101(1):3-12. PubMed ID: 12243733
[TBL] [Abstract][Full Text] [Related]
2. Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.
Kaba SA; Price A; Zhou Z; Sundaram V; Schnake P; Goldman IF; Lal AA; Udhayakumar V; Todd CW
Clin Vaccine Immunol; 2008 Nov; 15(11):1674-83. PubMed ID: 18784343
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application.
de Oliveira GA; Clavijo P; Nussenzweig RS; Nardin EH
Vaccine; 1994 Aug; 12(11):1012-7. PubMed ID: 7526570
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
[TBL] [Abstract][Full Text] [Related]
6. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli.
Zhou Z; Todd CW; Wohlhueter RM; Price A; Xiao L; Schnake P; Bonner PC; Martin AM; Goldman IF; De La Vega P; Udhayakumar V; Lal AA
Hum Vaccin; 2006; 2(1):14-23. PubMed ID: 17012909
[TBL] [Abstract][Full Text] [Related]
7. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.
Birkett A; Lyons K; Schmidt A; Boyd D; Oliveira GA; Siddique A; Nussenzweig R; Calvo-Calle JM; Nardin E
Infect Immun; 2002 Dec; 70(12):6860-70. PubMed ID: 12438363
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
9. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.
Calvo-Calle JM; Oliveira GA; Watta CO; Soverow J; Parra-Lopez C; Nardin EH
Infect Immun; 2006 Dec; 74(12):6929-39. PubMed ID: 17030584
[TBL] [Abstract][Full Text] [Related]
10. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
[TBL] [Abstract][Full Text] [Related]
11. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.
Shi YP; Hasnain SE; Sacci JB; Holloway BP; Fujioka H; Kumar N; Wohlhueter R; Hoffman SL; Collins WE; Lal AA
Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1615-20. PubMed ID: 9990073
[TBL] [Abstract][Full Text] [Related]
13. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.
Pirahmadi S; Zakeri S; Mehrizi AA; Djadid ND; Raz AA; Sani JJ
Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936155
[No Abstract] [Full Text] [Related]
14. Inclusion of an Optimized
Eacret JS; Parzych EM; Gonzales DM; Burns JM
J Immunol; 2021 Apr; 206(8):1817-1831. PubMed ID: 33789984
[No Abstract] [Full Text] [Related]
15. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
16. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.
Yang C; Collins WE; Sullivan JS; Kaslow DC; Xiao L; Lal AA
Infect Immun; 1999 Jan; 67(1):342-9. PubMed ID: 9864235
[TBL] [Abstract][Full Text] [Related]
17. Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood-stage antigens.
Chatterjee S; Sharma P; Kumar S; Chauhan VS
Vaccine; 1995; 13(15):1474-81. PubMed ID: 8578829
[TBL] [Abstract][Full Text] [Related]
18. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin.
Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA
Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208
[TBL] [Abstract][Full Text] [Related]
20. Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites.
Calvo-Calle JM; Oliveira GA; Nardin EH
J Immunol; 2005 Dec; 175(11):7575-85. PubMed ID: 16301667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
